Now showing items 1-4 of 4
The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: A placebo-controlled study
Objective: The present placebo-controlled study evaluated the efficacy, tolerability, and safety of 8-week treatment with agomelatine (25-50 mg/d by mouth) in elderly patients with major depressive disorder (MDD). Method: ...
Comorbidity and its relevance on general hospital based mortality in major depressive disorder: A naturalistic 12-year follow-up in general hospital admissions
Major depressive disorder (MDD) is associated with physical comorbidity, but the risk factors of general hospital-based mortality are unclear. Consequently, we investigated whether the burden of comorbidity and its relevance ...
Sustained efficacy and safety of agomelatine versus placebo over 24 weeks in elderly out-patients suffering from major depressive disorder
With an increasingly ageing population, there is a growing need to develop novel ways to treat depression in the elderly. Few published placebo-controlled study results in elderly depressed patients reached a clinical ...
Efficacy of agomelatine in more anxious elderly depressed patients. A randomized, double-blind study vs placebo.
Agomelatine, has been shown to be effective and well-tolerated, in treating: major depressive disorder, anxiety symptoms of depression (1,2) and Generalized Anxiety Disorder (3,4). The present analysis evaluate the ...